Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Express Scripts
Harvard Business School
Medtronic
Dow

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

FEMRING Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Femring patents expire, and when can generic versions of Femring launch?

Femring is a drug marketed by Millicent and is included in one NDA.

The generic ingredient in FEMRING is estradiol acetate. There are seventy-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the estradiol acetate profile page.

Drug patent expirations by year for FEMRING
Drug Prices for FEMRING

See drug prices for FEMRING

Drug Sales Revenue Trends for FEMRING

See drug sales revenues for FEMRING

Recent Clinical Trials for FEMRING

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Columbia UniversityN/A

See all FEMRING clinical trials

Pharmacology for FEMRING
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists
Synonyms for FEMRING
17beta-Estradiol 3-acetate
17beta-Hydroxy-3-acetoxyestra-1,3,5(10)-triene
17beta-Hydroxyestra-1,3,5(10)-trien-3-yl acetate
25975-62-6
3-(Acetyloxy)estra-1,3,5(10)-trien-17.beta.-ol
3-Acetoxy-oestra-1,3,5(10)-trien-17beta-ol
3-Acetoxyestra-1,3,5(10)-trien-17beta-ol
3-O-Acetylestradiol
4245-41-4
5R97F5H93P
beta-Estradiol 3-acetate
CAS-4245-41-4
CHEBI:135981
CHEMBL1200430
D04061
DSSTox_CID_25867
DSSTox_GSID_45867
DSSTox_RID_81186
DTXSID7045867
E 3A
E3A
Estra-1,3,5(10)-triene-3,17-diol, (17 beta)-, 3-acetate
Estra-1,3,5(10)-triene-3,17-diol, (17beta)-, 3-acetate
Estra-1,3,5(10)-triene-3,17beta-diyl 3-acetate
Estradiol 3-acetate
Estradiol acetate (USAN)
Estradiol acetate [USAN]
Estradiol-3-acetate
Estradiol, 3-acetate
FHXBMXJMKMWVRG-SLHNCBLASA-N
Menoring
NCGC00249885-01
SCHEMBL148561
Tox21_111359
Tox21_113661
UNII-5R97F5H93P

US Patents and Regulatory Information for FEMRING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millicent FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-001 Mar 20, 2003 RX Yes No   Start Trial   Start Trial   Start Trial
Millicent FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-002 Mar 20, 2003 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FEMRING

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Millicent FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-001 Mar 20, 2003   Start Trial   Start Trial
Millicent FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-002 Mar 20, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Colorcon
Medtronic
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.